This phase 3 , randomized , double-blind , placebo-controlled , comparative study aimed to confirm the superiority of 24 week luseogliflozin 2.5 mg monotherapy over placebo in reducing hemoglobin A1c ( HbA1c ) levels in Japanese patients with type 2 diabetes mellitus ( T2DM ) .